References
1. Cives, M. and J.R. Strosberg, Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin, 2018. 68 (6): p. 471-487.
2. Yao, J.C., et al., One hundred years after ”carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol, 2008. 26 (18): p. 3063-72.
3. Lee, K.J., et al., Clinicopathological characteristics of biliary neuroendocrine neoplasms: a multicenter study. Scand J Gastroenterol, 2017. 52 (4): p. 437-441.
4. Kim, S., et al., Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet, 2022.400 (10357): p. 1008-1019.
5. Palucka, A.K. and L.M. Coussens, The Basis of Oncoimmunology.Cell, 2016. 164 (6): p. 1233-1247.
6. Albores-Saavedra, J., et al., Carcinoid tumors and small-cell carcinomas of the gallbladder and extrahepatic bile ducts: a comparative study based on 221 cases from the Surveillance, Epidemiology, and End Results Program. Ann Diagn Pathol, 2009. 13 (6): p. 378-83.
7. Klein, O., et al., Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.JAMA Oncol, 2020. 6 (9): p. 1405-1409.
8. Ioka, T., et al., Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci, 2022.
9. Chen, H., Y.Y. Shen, and X.Z. Ni, Two cases of neuroendocrine carcinoma of the gallbladder. World J Gastroenterol, 2014.20 (33): p. 11916-20.
10. Yan, S., et al., Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma and Comparison with Gallbladder Adenocarcinoma Using a Propensity Score Matching. Cancer Manag Res, 2020. 12 : p. 1437-1446.
11. Yamaguchi, T., et al., Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci, 2014. 105 (9): p. 1176-81.
12. Mok, T.S.K., et al., Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 2019. 393 (10183): p. 1819-1830.
13. Rittmeyer, A., et al., Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 2017. 389 (10066): p. 255-265.
14. Hijioka, S., et al., Can EUS-guided FNA distinguish between gallbladder cancer and xanthogranulomatous cholecystitis? Gastrointest Endosc, 2010. 72 (3): p. 622-7.
15. Kojima, H., et al., Peritoneal dissemination of pancreatic cancer caused by endoscopic ultrasound-guided fine needle aspiration: A case report and literature review. World J Gastroenterol, 2021.27 (3): p. 294-304.
16. Priyanka Akhilesh, S., et al., Common Hepatic Duct Mixed Adenoneuroendocrine Carcinoma Masquerading as Cholangiocarcinoma. Case Rep Gastrointest Med, 2016. 2016 : p. 4827050.
17. Acosta, A.M. and E.L. Wiley, Primary Biliary Mixed Adenoneuroendocrine Carcinoma (MANEC): A Short Review. Arch Pathol Lab Med, 2016. 140 (10): p. 1157-62.